Loss of braking signals during inflammation: A factor affecting the development and disease course of multiple sclerosis

Archives of Neurology

Volumn 68, Issue 7, 2011, Pages 879-888

  Gilli, Francesca ^a   Navone, Nicole Désirée ^a   Perga, Simona ^a   Marnetto, Fabiana ^a   Caldano, Marzia ^a   Capobianco, Marco ^a   Pulizzi, Annalisa ^a   Malucchi, Simona ^a   Bertolotto, Antonio ^a  

^a SAN LUIGI GONZAGA UNIVERSITY HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; NATALIZUMAB;

ADOLESCENT; ADULT; AGED; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CXCR4 GENE; DISEASE COURSE; DOWN REGULATION; EXPANDED DISABILITY STATUS SCALE; FAM49B GENE; FEMALE; FOLLOW UP; GENE; GENE EXPRESSION; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NR4A2 GENE; POLR2J GENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; SOCS2 GENE; STAG3L1 GENE; TNFAIP3 GENE;

ADOLESCENT; ADULT; AGED; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; IMMUNOLOGIC FACTORS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NUCLEAR PROTEINS; NUCLEAR RECEPTOR SUBFAMILY 4, GROUP A, MEMBER 2; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECURRENCE; SIGNAL TRANSDUCTION; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; YOUNG ADULT;

EID: 79960171362     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2011.32     Document Type: Article

References (40)

1. Al-Shammri S, Rawoot P, Azizieh F, et al. Th1/Th2 cytokine patterns and clinical profiles during and after pregnancy in women with multiple sclerosis. J Neurol Sci. 2004;222(1-2):21-27. (Pubitemid 38881502)
2. Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T; Pregnancy in Multiple Sclerosis Group. Rate of pregnancy-related relapse in multiple sclerosis. N Engl J Med. 1998;339(5):285-291. (Pubitemid 28366416)
3. Gordon C. Pregnancy and autoimmune diseases. Best Pract Res Clin Rheumatol. 2004;18(3):359-379. (Pubitemid 38950058)
4. Gilli F, Lindberg RLP, Valentino P, et al. Learning from nature: pregnancy changes the expression of inflammation-related genes in patients with multiple sclerosis. PLoS One. 2010;5(1):e8962.
5. López C, Comabella M, Tintoré M, Sastre-Garriga J, Montalban X. Variations in chemokine receptor and cytokine expression during pregnancy in multiple sclerosis patients. Mult Scler. 2006;12(4):421-427. (Pubitemid 44132582)
6. De Jager PL, Jia X, Wang J, et al; International MS Genetics Consortium. Metaanalysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet. 2009;41(7):776-782.
7. Tsao JT, Kuo CC, Lin SC. The analysis of CIS, SOCS1, SOSC2 and SOCS3 transcript levels in peripheral blood mononuclear cells of systemic lupus erythematosus and rheumatoid arthritis patients. Clin Exp Med. 2008;8(4):179-185.
8. Fung EY, Smyth DJ, Howson JM, et al. Analysis of 17 autoimmune disease-associated variants in type 1 diabetes identifies 6q23/TNFAIP3 as a susceptibility locus. Genes Immun. 2009;10(2):188-191.
9. Duan R, Leo P, Bradbury L, Brown MA, Thomas G. Gene expression profiling reveals a downregulation in immune-associated genes in patients with AS. Ann Rheum Dis. 2010;69(9):1724-1729.
10. Heyninck K, Beyaert R. A20 inhibits NF-kappaB activation by dual ubiquitinediting functions. Trends Biochem Sci. 2005;30(1):1-4. (Pubitemid 40093732)
11. Vereecke L, Beyaert R, van Loo G. The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. Trends Immunol. 2009;30(8):383-391.
12. Verstrepen L, Verhelst K, van Loo G, Carpentier I, Ley SC, Beyaert R. Expression, biological activities and mechanisms of action of A20 (TNFAIP3). Biochem Pharmacol. 2010;80(12):2009-2020.
13. Saijo K, Winner B, Carson CT, et al. A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell. 2009;137(1):47-59.
14. Rico-Bautista E, Flores-Morales A, Fernández-Pérez L. Suppressor of cytokine signaling (SOCS) 2, a protein with multiple functions. Cytokine Growth Factor Rev. 2006;17(6):431-439. (Pubitemid 44793121)
15. Meiron M, Zohar Y, Anunu R, Wildbaum G, Karin N. CXCL12 (SDF-1alpha) suppresses ongoing experimental autoimmune encephalomyelitis by selecting antigenspecific regulatory T cells. J Exp Med. 2008;205(11):2643-2655.
16. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. Cell. 2010;140(6):918-934.
17. McMahon EJ, Bailey SL, Castenada CV, Waldner H, Miller SD. Epitope spreading initiates in the CNS in twomouse models of multiple sclerosis. NatMed. 2005; 11(3):335-339. (Pubitemid 40460563)
18. Kidd BA, Ho PP, Sharpe O, et al. Epitope spreading to citrullinated antigens in mouse models of autoimmune arthritis and demyelination. Arthritis Res Ther. 2008;10(5):R119.
19. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol. 2005;58(6):840-846.
20. Bertolotto A, Malucchi S, Sala A, et al. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory. J Neurol Neurosurg Psychiatry. 2002;73(2):148-153.
21. Calabresi PA, Giovannoni G, Confavreux C, et al; AFFIRM and SENTINEL Investigators. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology. 2007;69(14):1391-1403. (Pubitemid 47511460)
22. Schumacker GA, Beebe G, Kibler RF, et al. Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann N Y Acad Sci. 1965;122: 552-568.
23. Bertolotto A, Gilli F, Sala A, et al. Persistent neutralizing antibodies abolish the interferon β bioavailability in MS patients. Neurology. 2003;60(4):634-639. (Pubitemid 36246082)
24. Gilli F, Bertolotto A, Sala A, et al. Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs. Brain. 2004;127(Pt 2):259-268. (Pubitemid 38160311)
25. PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology. 2001;56(12):1628-1636.
26. Malucchi S, Sala A, Gilli F, et al. Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis. Neurology. 2004;62(11):2031-2037. (Pubitemid 38738217)
27. Kappos L, Clanet M, Sandberg-Wollheim M, et al; European Interferon Beta-1a IM Dose-Comparison Study Investigators. Neutralising antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology. 2005;65:40-47. (Pubitemid 40967774)
28. 4 and aspirin-triggered lipoxin are SOCS-2 dependent. Nat Med. 2006;12(3): 330-334.
29. Frischer JM, Bramow S, Dal-Bianco A, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain. 2009;132(pt 5):1175-1189.
30. Achiron A, Grotto I, Balicer R, Magalashvili D, Feldman A, Gurevich M. Microarray analysis identifies altered regulation of nuclear receptor family members in the pre-disease state of multiple sclerosis. Neurobiol Dis. 2010;38(2):201-209.
31. Glass CK, Saijo K. Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells. Nat Rev Immunol. 2010;10(5):365-376.
32. Hall JM, Korach KS. Stromal cell-derived factor 1, a novel target of estrogen receptor action, mediates the mitogenic effects of estradiol in ovarian and breast cancer cells. Mol Endocrinol. 2003;17(5):792-803. (Pubitemid 36539573)
33. Vendrell JA, Ghayad S, Ben-Larbi S, Dumontet C, Mechti N, Cohen PA. A20/ TNFAIP3, a new estrogen-regulated gene that confers tamoxifen resistance in breast cancer cells. Oncogene. 2007;26(32):4656-4667. (Pubitemid 47067412)
34. Comabella M, Lünemann JD, Río J, et al. A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. Brain. 2009;132(pt 12):3353-3365.
35. Brender C, Nielsen M, Röpke C, et al. Interferon-alpha induces transient suppressors of cytokine signalling expression in human T cells. Exp Clin Immunogenet. 2001;18(2):80-85. (Pubitemid 32429672)
36. Jin L, Tabe Y, Konoplev S, et al. CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells. Mol Cancer Ther. 2008;7(1):48-58.
37. Yong VW, Chabot S. inventors; Teva Pharmaceutical Industries Ltd, assignee. Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders. US patent application 7,033,582 B2. April 25, 2005.
38. Hutchinson M. Natalizumab: a new treatment for relapsing remitting multiple sclerosis. Ther Clin Risk Manag. 2007;3(2):259-268. (Pubitemid 46881453)
39. Shah MV, Zhang R, Irby R, et al. Molecular profiling of LGL leukemia reveals role of sphingolipid signaling in survival of cytotoxic lymphocytes. Blood. 2008; 112(3):770-781.
40. Kivisäkk P, Healy BC, Viglietta V, et al. Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells. Neurology. 2009;72(22): 1922-1930.